Drug Type Small molecule drug |
Synonyms BMS 986299 |
Target |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | US | 05 Apr 2018 |
NCT03444753 (ASCO2023) Manual | Phase 1 | 50 | (Part 1A) | bnplqkvtqt(qmfireicgi) = fxxmenhcgr qgmlaeekfs (vffszdxcqt ) View more | Negative | 31 May 2023 | |
(Part 1B) | bnplqkvtqt(qmfireicgi) = siqxfhrtye qgmlaeekfs (vffszdxcqt ) View more |